BUZZ-MeiraGTx rises on positive data from genetic eye condition treatment

Reuters
02-21
BUZZ-MeiraGTx rises on positive data from genetic eye condition treatment

** Shares of gene therapy company MeiraGTx Holdings plc MGTX.O up 13.6% at $7.76 premarket

** Co says early-stage study data for its experimental gene therapy, rAAV8.hRKp.AIPL1, showed safety, efficacy and meaningful responses for treatment of genetic eye condition called retinal dystrophy

** Says children who were blind at birth were treated with the gene therapy and showed visual acuity in eyes after four or more weeks in small study

** The therapy showed improved functional vision and evidence of protection against progressive retinal degeneration, without serious adverse effects

** Retinal dystrophy is caused due to genetic deficiency of type of protein called AIPL1, which leads severe impairment of sight from birth

** Co says study data is published in medical journal The Lancet

** MGTX stock has risen ~16% in last 12 months

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10